EXAI Stock Overview
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs.
Exscientia plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.96|
|52 Week High||US$24.99|
|52 Week Low||US$4.90|
|1 Month Change||-28.32%|
|3 Month Change||-45.01%|
|1 Year Change||-79.45%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-81.70%|
Recent News & Updates
|EXAI||US Biotechs||US Market|
Return vs Industry: EXAI underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: EXAI underperformed the US Market which returned -21.2% over the past year.
|EXAI Average Weekly Movement||11.5%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: EXAI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: EXAI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates.
Exscientia plc Fundamentals Summary
|EXAI fundamental statistics|
Is EXAI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EXAI income statement (TTM)|
|Cost of Revenue||UK£28.59m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.81|
|Net Profit Margin||-406.22%|
How did EXAI perform over the long term?See historical performance and comparison